Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Fujioka

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|May 16, 2018
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 StudyDouglas L Seidner, Ken Fujioka, Joseph I Boullata, et al.
Plos One|March 19, 2015
Obesity impairs γδ T cell homeostasis and antiviral function in humansAnne E Costanzo, Kristen R Taylor, Shelley Dutt, et al.
Diabetes Care|October 23, 2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetesPriscilla Hollander, Alok K Gupta, Raymond Plodkowski, et al.
Lancet (London, England)|August 3, 2010
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialFrank L Greenway, Ken Fujioka, Raymond A Plodkowski, et al.
The Journal of Clinical Endocrinology and Metabolism|May 17, 2007
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation studyLouis Aronne, Ken Fujioka, Vanita Aroda, et al.
Obesity (Silver Spring, Md.)|April 26, 2017
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety studySteven R Smith, W Timothy Garvey, Frank L Greenway, et al.
Obesity (Silver Spring, Md.)|January 25, 2018
Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized SubstudyCandida J Rebello, Elena V Nikonova, Sharon Zhou, et al.
Clinical and Translational Gastroenterology|February 5, 2016
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel SyndromeLauren K Schwartz, Stephen J D O'Keefe, Ken Fujioka, et al.
Obesity (Silver Spring, Md.)|November 3, 2016
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical MarkersKen Fujioka, Patrick M O'Neil, Melanie Davies, et al.
Obesity Surgery|May 28, 2016
Understanding the Capacity for Exercise in Post-Bariatric PatientsKaren J Coleman, Susan L Caparosa, Jeanne F Nichols, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition|May 16, 2018
Reduction of Parenteral Nutrition and Hydration Support and Safety With Long-Term Teduglutide Treatment in Patients With Short Bowel Syndrome-Associated Intestinal Failure: STEPS-3 StudyDouglas L Seidner, Ken Fujioka, Joseph I Boullata, et al.
Plos One|March 19, 2015
Obesity impairs γδ T cell homeostasis and antiviral function in humansAnne E Costanzo, Kristen R Taylor, Shelley Dutt, et al.
Diabetes Care|October 23, 2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetesPriscilla Hollander, Alok K Gupta, Raymond Plodkowski, et al.
Lancet (London, England)|August 3, 2010
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialFrank L Greenway, Ken Fujioka, Raymond A Plodkowski, et al.
The Journal of Clinical Endocrinology and Metabolism|May 17, 2007
Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation studyLouis Aronne, Ken Fujioka, Vanita Aroda, et al.
Obesity (Silver Spring, Md.)|April 26, 2017
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety studySteven R Smith, W Timothy Garvey, Frank L Greenway, et al.
Obesity (Silver Spring, Md.)|January 25, 2018
Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized SubstudyCandida J Rebello, Elena V Nikonova, Sharon Zhou, et al.
Clinical and Translational Gastroenterology|February 5, 2016
Long-Term Teduglutide for the Treatment of Patients With Intestinal Failure Associated With Short Bowel SyndromeLauren K Schwartz, Stephen J D O'Keefe, Ken Fujioka, et al.
Obesity (Silver Spring, Md.)|November 3, 2016
Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical MarkersKen Fujioka, Patrick M O'Neil, Melanie Davies, et al.
Obesity Surgery|May 28, 2016
Understanding the Capacity for Exercise in Post-Bariatric PatientsKaren J Coleman, Susan L Caparosa, Jeanne F Nichols, et al.
Pageof 7